Response Criteria in Urologic Malignancies
The recognition of a response to treatment in prostatic carcinoma is not qualitatively different than that in other solid tumors; nonetheless, the preponderance of bone as a site of metastases in prostate cancer makes effective measurement of response difficult. In other disease sites, such as colorectal cancer or lung cancer, inability to detect early and quantitative changes on bone scan (i.e., 25% versus 50% improvement) are of less clinical importance. In these tumors there are indicator lesions in lung, soft tissue, etc. which can be easily measured and quantitated. In contrast, in prostatic carcinoma, for the vast majority of patients, bone is the only site of metastatic disease and the dominant site of symptomatic disease.
KeywordsEstrogen Platinum Adenocarcinoma Anemia Quinone
Unable to display preview. Download preview PDF.
- 1.Bagshaw MA (1978) Radiation therapy for cancer of the prostate. In: Skinner DG, de Kernion JB (eds) Genitourinary cancer. Saunders, New York, p 358Google Scholar
- 2.Byar DP (1977) VACURG studies on prostatic cancer and its treatment. In: Tannenbaum M (ed) Urologie pathology: the prostate. Lea & Febiger, Philadelphia, pp 241–267Google Scholar
- 10.Hovsepian JA, Byar DP and the VACURG (1978) Quantitative radiology of responses to endocrine therapy in stage 4 adenocarcinoma of the prostate. Proc AACR and ASCO 19:307Google Scholar
- 21.Resnick MI, Willard JW, Boyce WH (1981) Ultrasonic evaluation of the prostatic nodule. J Urol 120:86–89Google Scholar